Document:

LOAN
AGREEMENT (Amendment 5) made effective March 21, 2016 (the “Effective Date”) between Mercuriali Ltd., a
limited company incorporated pursuant to the laws of England and Wales (hereinafter referred to as “Mercuriali”) and
Samuel Asculai of the City of Toronto (hereinafter “Asculai”) and Enhance Skin Products Inc., a
corporation incorporated pursuant to the laws of the State of Nevada (hereinafter referred to as “Enhance”)

 

WHEREAS
Mercuriali, Asculai and Enhance are parties to a Loan Agreement dated March 4, 2013 (hereinafter the “Loan Agreement”),
a Loan Agreement (Amendment 1) made effective September 20, 2013 (hereinafter “Amendment Agreement 1), a Loan Agreement
(Amendment 2) made effective March 3, 2014 (hereinafter “Amendment Agreement 2), a Loan Agreement (Amendment 3) made effective
September 29, 2015 (hereinafter “Amendment Agreement 3) and a Loan Agreement (Amendment 4) made effective January 22, 2016
(hereinafter “Amendment Agreement 4”);

 

AND
WHEREAS Enhance and Vis Vires Group Inc. are parties to a Convertible Promissory Note dated June 19, 2015 (“The Vis Vires
Promissory Note”) and a Securities Purchase Agreement dated June 19, 2015 (“The Vis Vires Securities Purchase Agreement”);

 

AND
WHEREAS the parties wish to amend the Loan Agreement, Amendment Agreement 1,Amendment Agreement 2, Amendment Agreement 3 and Amendment
Agreement 4;

 

NOW
THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the mutual covenants contained herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed as follows:

 

1.
Loan Amounts.

 

	(a)	As
    of January 31, 2015 (“Amended Reporting Date”), Asculai has loaned Enhance $96,489 under the Loan Agreement (hereinafter
    the “Asculai Loan Amount”). The Asculai Loan Amount will be increased by any amount loaned by Asculai to Enhance
    since the Amended Reporting Date or during the term of this Agreement. 
	 	 
	(b)	As
    of the Amended Reporting Date, Enhance owes Mercuriali $216,711 under the Loan Agreement (hereinafter “the “Mercuriali
    Loan Amount”) and $50,475 under the Additional Mercuriali Loan Amount. The Mercuriali Loan Amount will be increased
    in the event that Mercuriali loans additional monies to Enhance since the Amended Reporting Date or during the term of this
    Agreement.
	 	 
	(c)	Asculai
    and Mercuriali have agreed jointly or individually to increase the additional loan under Amendment 4 from $90,000 to $150,000
    (“The Additional Asculai Loan Amount” and/or “The Additional Mercuriali Loan Amount”) in the event
    no additional third party monies are received.

 

2.
Amendment to Conversion Loan Amounts.

 

Section
3 of the Loan Agreement, as amended by Amendment Agreements 1, 2, 3 and/or 4, is amended by deleting it and replacing it with
the following:

 

    	 		 

    	 		 

    

 

3.
Conversion of Loan Amounts.

 

(a) Upon
Enhance restructuring at least seventy five percent (75%) of its outstanding debt substantially in accordance with the restructuring
plan approved by the Board of Directors of Enhance on February 13, 2013, Asculai shall convert fifty percent (50%) of the Asculai
Loan Amount into common shares of Enhance at a conversion price of $0.00376 per share (the “Conversion Price”). Upon
Enhance receiving aggregate Transaction Monies (as defined below in Section 3(g)) of at least two hundred and fifty thousand United
States dollars (US$250,000) the remainder of the Asculai Loan Amount (the “Remaining Asculai Loan Amount”) shall become
unsecured and shall be repaid as set out in Section 4 below.

 

(b) Upon
Enhance restructuring at least seventy five percent (75%) of its outstanding debt substantially in accordance with the restructuring
plan approved by the Board of Directors of Enhance on February 13, 2013 and upon Enhance receiving aggregate Transaction Monies
(as defined below in Section 3(g)) of at least two hundred and fifty thousand United States dollars (US$250,000), Mercuriali shall
convert the Mercuriali Loan Amount into common shares of Enhance at the Conversion Price.

 

(c) Upon
Enhance receiving aggregate Transaction Monies (as defined below in Section 3(g) of at least two hundred and fifty thousand United
States dollars (US$250,000) (“Transaction Monies Threshold”), Mercuriali shall convert the Additional Mercuriali Loan
Amount into common shares of Enhance at $0.0018 (the “Additional Loan Conversion Price”).

 

(d) Upon
Enhance receiving aggregate Transaction Monies (as defined below in Section 3(g) of at least two hundred and fifty thousand United
States dollars (US$250,000), Asculai shall convert the Additional Asculai Loan Amount into common shares of Enhance at the Additional
Loan Conversion Price.

 

(e) In
the event of an Tender Offer for or an agreement for Enhance’s sale, merger, or other business combination (“Transaction”)
Mercuriali shall have the full right, but not the obligation, to convert the Mercuriali Loan Amount and The Additional Mercuriali
Loan Amount into common shares of Enhance at the Conversion Price or Additional Loan Conversion Price, as applicable, and to participate
in such Transaction on an equal basis to existing shareholders of Enhance.

 

(f) In
the event of an Tender Offer for or an agreement for Enhance’s sale, merger, or other business combination (“Transaction”)
Asculai shall have the full right, but not the obligation, to convert The Additional Asculai Loan Amount into common shares of
Enhance at the Additional Loan Conversion Price and to participate in such Transaction on an equal basis to existing shareholders
of Enhance.

 

(g) Transaction
Monies shall mean any monies, and the total amount of any other readily realizable cash equivalents or other assets received by
Enhance or any of its affiliates from third parties, in respect of any debt financing, equity financing, sale of assets or royalty
interest, licensing fees or any other similar funding method including in consequence of any merger or sale of all or part of
the Corporation’s business.

 

    	 		 

    	 		 

    

 

3.
Conflicts.

 

Except
as set out in this Amendment Agreement, the Loan Agreement, Amendment Agreement 1, Amendment Agreement 2, Amendment Agreement
3 and Amendment Agreement 4 are unaffected and shall continue in full force and effect in accordance with their terms. If there
is any conflict between any provision of this Amendment Agreement and the Loan Agreement, and/or Amendment Agreements 1, 2, 3
and/or 4, the terms of this Amendment Agreement shall prevail.

 

4.
Governing Law.

 

This
Amendment Agreement and all of the rights and obligations arising herefrom shall be interpreted and applied in accordance with
the laws of the State of Nevada and the courts of the State of Nevada shall have exclusive jurisdiction to determine all disputes
relating to the Agreement and all of the rights and obligations created hereby.

 

IN
WITNESS WHEREOF the parties here have caused this Agreement to be executed and delivered effective as of the date first written
above.

 

	MERCURIALI
    LTD.	 	ENHANCE
    SKIN PRODUCTS INC.	 	SAMUEL
    ASCULAI
	 	 	 	 	 
	 	 	 	 	 
	Donald
    Nicholson	 	Drasko
    Puseljic	 	 
	Chief
    Executive	 	General
    CounselAMENDMENT
NO. 3 TO CONSULTING AGREEMENT

 

B
E T W E E N:

 

SAMUEL
ASCULAI

of
the City of Toronto

in
the Province of Ontario

 

(hereinafter
referred to as the “Principal”)

 

 - and -

 

BIOSTRATEGIES
CONSULTING GROUP INC.

a
corporation incorporated pursuant to the

laws
of the Province of Ontario

 

(hereinafter
referred to as the “Consultant”)

 

-
and -

 

ENHANCE
SKIN PRODUCTS INC.

a
corporation incorporated pursuant to the

laws
of the State of Nevada

 

(hereinafter
referred to as the “Corporation”)

 

WHEREAS
the Corporation, Consultant and Principal are parties to a Consulting Agreement made effective March 5, 2013, Amendment No 1 to
Consulting Agreement dated March 3, 2014 and Amendment No 2 to Consulting Agreement effective August 1, 2015 (collectively the
“Consulting Agreement”);

 

AND
WHEREAS Corporation and Vis Vires Group Inc. are parties to a Convertible Promissory Note dated June 19, 2015 (“The Vis
Vires Promissory Note”) and a Securities Purchase Agreement dated June 19, 2015 (“The Vis Vires Securities Purchase
Agreement”);

 

AND
WHEREAS the parties hereto wish to amend the terms of the Consulting Agreement with effect from March 21, 2016 (“Effective
date”);

 

NOW
THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the mutual covenants contained herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed as follows:

 

    	 		 

    	 	- 2 -	 

    

 

	1.	Section
    2.01(c) of the Consulting Agreement, is amended by deleting it and replacing it with the following:

 

(c)
Prior to receipt of Threshhold Funding, payments required to be made under this Section 2.01 shall be made as follows:

 

	 	(1)	For
    the period August 1, 2015 to October 31, 2015 the Corporation shall pay the Consultant the sum of twenty one thousand United
    States dollars (US$21,000) to be satisfied seventy percent (70%) in common shares of the Corporation at the price of $0.0018
    and thirty percent (30%) in cash, all such payments to be made within 30 days of the receipt of Threshhold Funding.
	 	 	 
	 	(2)	For
    the period November 1, 2015 to January 31, 2016 the Corporation shall pay the Consultant for the value Services provided in
    that period to be satisfied seventy percent (70%) in common shares of Corporation at the price of $0.0018 and thirty percent
    (30%) in cash, all such payments to be made within 30 days of the receipt of Threshhold Funding.
	 	 	 
	 	(3)	For
    the period from February 1, 2016 the Corporation shall pay the Consultant for the value of Services provided in that period
    to be satisfied 70% in common shares of Corporation at the weighted average price of the new shares issued to non-related
    third parties after the Effective date (excluding shares issued under The Vis Vires Promissory Note) and 30% in cash, all
    such payments to be made within 30 days of the receipt of Threshhold Funding.

 

The
Corporation’s obligation to make payments under this Section 2.01(c) is contingent upon the Corporation receiving Threshhold
Funding by April 30, 2017.

 

	2.	Except
    as set out in this Amendment Agreement, the Consulting Agreement is unaffected and shall continue in full force and effect
    in accordance with its terms. If there is any conflict between any provision of this Amendment Agreement and the Consulting
    Agreement, the terms of this Amendment Agreement shall prevail.
	 	 
	3.	This
    Agreement and all of the rights and obligations arising herefrom shall be interpreted and applied in accordance with the laws
    of the Province of Ontario and the courts of the Province of Ontario shall have exclusive jurisdiction to determine all disputes
    relating to the Agreement and all of the rights and obligations created hereby. The Consultant and the Corporation hereby
    irrevocably attorn to the jurisdiction of the courts of the Province of Ontario.

 

    	 		 

    	 	- 3 -	 

    

 

IN
WITNESS WHEREOF the parties here have caused this Agreement to be executed.

 

	SIGNED,
    SEALED AND DELIVERED	)
	 	 
	 	 
	 	Samuel
    Asculai
	 	 
	 	 
	 	BIOSTRATEGIES
    CONSULTING GROUP INC.
	 	Per:
    Samuel Asculai, President & CEO
	 	 
	 	 
	 	ENHANCE
    SKIN PRODUCTS INC.
	 	Per:
    Donald Nicholson, President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]